New research supported by the Knight Initiative for Brain Resilience at Stanford’s Wu Tsai Neurosciences Institute highlights significant strides researchers have made in developing biomarkers for the early detection and monitoring of neurodegenerative diseases—including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Lewy body disease (LBD).